mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.001 |
mRNA |
Methotrexate |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
0.002 |
mRNA |
RDEA119 |
GDSC1000 |
pan-cancer |
AAC |
-0.095 |
0.002 |
mRNA |
austocystin d |
CTRPv2 |
pan-cancer |
AAC |
-0.12 |
0.002 |
mRNA |
erlotinib:PLX-4032 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.12 |
0.002 |
mRNA |
PD 153035 |
CTRPv2 |
pan-cancer |
AAC |
-0.13 |
0.002 |
mRNA |
PD318088 |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.002 |
mRNA |
trifluoperazine |
CTRPv2 |
pan-cancer |
AAC |
-0.12 |
0.002 |
mRNA |
VX-11e |
GDSC1000 |
pan-cancer |
AAC |
-0.096 |
0.003 |
mRNA |
Teniposide |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
0.004 |